OSTEOARTHRITIS
A randomized clinical trial to evaluate two doses of an intra-articular injection of LMWF-5A in adults with pain due to osteoarthritis of the knee
This report has been verified
by one or more authors of the
original publication.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2014;2(11):18 PLoS One. 2014 Feb 3;9(2):e87910. doi: 10.1371/journal.pone.0087910. eCollection 2014.329 patients with symptomatic knee osteoarthritis (OA) were randomized to receive either Low Molecular Weight Fraction of 5% human serum albumin (LMWF-5A) or saline vehicle solution, each at a dose of either 4 or 10 mL. The purpose of this study was to determine the analgesic efficacy and safety of LMWF-5A in this study population. Results indicated that both the 4-mL and 10-mL volumes of the LMWF-5A solution were safe and yielded significantly better pain scores, functional outcome, and overall assessment of disease severity, when compared to a saline vehicle solution. These effects were especially pronounced in patients with severe OA, and those who received a prior knee injection.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Ja = 1
Ungewiss = 0.5
Nicht relevant = 0
Nein = 0
Die Bewertung der Berichtskriterien bewertet die Transparenz, mit der die Autoren die methodischen und studienspezifischen Merkmale der Studie in der Veröffentlichung angeben. Die Bewertung ist in fünf Kategorien unterteilt, die im Folgenden vorgestellt werden.
4/4
التوزيع العشوائي
3/4
قياسات النتائج
4/4
الشمول / الاستبعاد
4/4
وصف العلاج
4/4
الإحصاء
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
Der Fragilitätsindex ist ein Instrument, das bei der Interpretation signifikanter Ergebnisse hilft und ein Maß für die Stärke eines Ergebnisses liefert. Der Fragilitätsindex gibt die Anzahl der aufeinanderfolgenden Ereignisse an, die zu einem dichotomen Ergebnis hinzugefügt werden müssen, damit das Ergebnis nicht mehr signifikant ist. Eine kleine Zahl steht für ein schwächeres Ergebnis und eine große Zahl für ein stärkeres Ergebnis.
Warum wurde diese Studie jetzt benötigt?
The prevalence of knee osteoarthritis (OA) is on the rise. This increase - potentially attributable (in part) to the increasing rates of obesity within the population - in concerning, as knee OA can significantly impact a patient's quality of life. Currently, conservative treatment for this inflammatory condition may include intra-articular corticosteroid or hyaluronan injections, or non-steroidal anti-inflammatory drugs (NSAIDs); however, these approaches are not supported by high-quality evidence. As a result, human serum albumin (HSA) has been proposed as an alternative in the management of knee OA. This study was needed to establish the analgesic efficacy and safety of the Low Molecular Weight Fraction of 5% HSA (LMWF-5A) for the treatment of patients with knee OA.
Was war die wichtigste Forschungsfrage?
Is the Low Molecular Weight Fraction of 5% human serum albumin (LMWF-5A) safe and effective for improving pain, stiffness, function and overall disease severity in patients with knee osteoarthritis?
Was waren die wichtigsten Ergebnisse?
- In general, LMWF-5A improved pain significantly more (-0.93) compared to the control solution (-0.72) (estimated difference: -0.25; 95% CI -0.08 to -0.41; p=0.004). This significant between-group difference was apparent at week 4 (p=0.03), week 6 (p=0.04) and week 12 (p=0.004), but not at weeks 2 (p=0.14), 8 (p=0.06) or 10 (p=0.11).
- Over time ending at week 12, the percentage of pain score reduction was significantly greater when patients were administered LMWF-5A (42.3%) compared to the control solution (31.7%) (p<0.05).
- Compared to patients receiving the saline vehicle solution, those receiving LMWF-5A had significantly superior Patient's Global Assessment (PGA) of disease severity scores (-0.87 vs -0.65; p=0.01), physical function (-0.78 vs -0.64; p=0.04) and pain at rest (-0.91 vs -0.70; p=0.004).
- Whether patients were administered LMWF-5A or the saline vehicle solution, there was no significant difference in the number of acetaminophen pills consumed (median 24.0 vs 34.0; p=0.09), or stiffness (p>0.05).
- In patients with severe OA, LMWF-5A had a significant pain improvement compared to the saline solution (-0.42; 95% CI -0.08 to -0.77; p=0.02). Furthermore, patients who had previously received a knee injection had a significantly better mean pain outcome with LMWF-5A compared to control, whereas this finding was borderline-significant in patients who did not receive a previous injection.
- Between the LMWF-5A and control in injection groups, there were no significant differences in total adverse events (41% vs 47%), treatment-related adverse events (10% vs 13%), or serious adverse events (5% vs 6%). No serious adverse event was considered to be study-related and no deaths occurred.
Was sollte ich mir besonders merken?
In patients with knee osteoarthritis (OA), both the 4-mL and 10-mL volumes of the Low Molecular Weight Fraction of 5% human serum albumin (LMWF-5A) were safe and yielded significantly better pain scores, functional outcome, and overall assessment of disease severity, when compared to a saline vehicle solution. These effects were especially pronounced in patients with severe OA, and those who had received a prior knee injection. Stiffness and the amount of rescue analgesics consumed were not significantly different between groups.
Wie wird sich dies auf die Behandlung meiner Patienten auswirken?
Results from this study support the administration of a single, intra-articular injection of Low Molecular Weight Fraction of 5% human serum albumin (LMWF-5A) in the treatment of knee osteoarthritis (OA). This finding is promising in patients with severe OA, for whom the only other treatment alternative may be surgical intervention. Additional long-term studies, with larger sample sizes, are needed to confirm these results.
HAFTUNGSAUSSCHLUSS
Der Inhalt dieser Seite dient nur zu Informationszwecken und ist nicht als Ersatz für professionelle medizinische Beratung, Diagnose oder Behandlung gedacht. Wenn Sie eine medizinische Behandlung benötigen, wenden Sie sich immer an Ihren Arzt oder suchen Sie die nächstgelegene Notaufnahme auf. Die Meinungen, Überzeugungen und Standpunkte, die von den Personen auf dieser Seite geäußert werden, spiegeln nicht die Meinungen, Überzeugungen und Standpunkte von OrthoEvidence wider.
0 von 4 monatliche KOSTENLOSE Artikel freigeschaltet
